Literature DB >> 8668653

Interaction between oxytocin and 'sidaverin' on the gravid and non-gravid rat uterus.

G D Lutterodt1.   

Abstract

Sidaverin, a crystalline compound extracted from a polar fraction of Sida veronicaefolia (Lam), elicited oxytocin-like contractions in the non-gravid rat isolated uterus preparation with a concentration-response relationship. Equipotent concentrations of oxytocin and sidaverin, using matched responses, were approximately 0.16 U and 0.4 micrograms ml-1, respectively. Sidaverin-induced contractile response was atropine reversible. The concentration-response curves for sidaverin and oxytocin were parallel, and both responses were inhibited by the specific oxytocin antagonist, Atosiban, indicating possible involvement of oxytocin receptors in the action of sidaverin. There were potentiation of action of one drug to that of the other, irrespective of the order of administration and even after washing off the first before introducing the second drug. In the gravid uterus, sidaverin produced contractions in preparations from day 1 to day 6 or 7, caused relaxation in days 7-11, and elicited contractions in day 11 through term, the sensitivity of the preparations increasing exponentially toward term with strong sustained contractions. With the exception of days 7-11, when sidaverin antagonized oxytocin action, it potentiated action of oxytocin on the gravid uterus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8668653     DOI: 10.1016/s1043-6618(95)80014-x

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  1 in total

1.  Efficacy of Sida pilosa Retz aqueous extract against Schistosoma mansoni - induced granulomatous inflammation in the liver and the intestine of mice: histomorphometry and gastrointestinal motility evaluation.

Authors:  Hermine Boukeng Jatsa; Ulrich Membe Femoe; Joseph Njiaza; Daniel Simplice Tombe Tombe; Lohik Nguegan Mbolang; Emilienne Tienga Nkondo; Louis-Albert Tchuem Tchuente; Théophile Dimo; Pierre Kamtchouing
Journal:  BMC Complement Altern Med       Date:  2018-09-06       Impact factor: 3.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.